Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMDNASDAQ:MDXGNYSE:NVRONASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$15.16-0.4%$14.33$13.14▼$19.85$957.95M1.951.23 million shs595,953 shsMDXGMiMedx Group$6.29+0.9%$6.50$5.47▼$10.14$928.29M1.76675,108 shs319,320 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81800,223 shs753,602 shsSIBNSiBone$18.46+0.2%$17.82$11.70▼$20.05$786.77M0.93395,377 shs288,621 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode0.00%+6.80%+7.03%-1.59%-12.75%MDXGMiMedx Group0.00%+5.81%-3.16%-11.35%-7.44%NVRONevro0.00%0.00%0.00%0.00%-32.10%SIBNSiBone0.00%+0.16%-2.33%+37.05%+42.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINMDInMode3.3331 of 5 stars3.13.00.00.03.11.71.9MDXGMiMedx Group3.4324 of 5 stars3.53.00.00.00.63.31.9NVRONevro0.1712 of 5 stars1.00.00.00.00.01.70.6SIBNSiBone4.1495 of 5 stars2.55.00.03.32.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMDInMode 2.13Hold$18.5422.35% UpsideMDXGMiMedx Group 3.00Buy$12.5098.89% UpsideNVRONevro 1.92Reduce$5.36-8.29% DownsideSIBNSiBone 3.00Buy$22.5021.89% UpsideCurrent Analyst Ratings BreakdownLatest NVRO, INMD, MDXG, and SIBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025SIBNSiBoneTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.005/6/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/6/2025SIBNSiBoneNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/30/2025INMDInModeBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $24.004/29/2025INMDInModeUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$19.00 ➝ $16.254/29/2025INMDInModeCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$17.00 ➝ $15.004/29/2025INMDInModeBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/28/2025INMDInModeBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2025INMDInModeRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$22.00 ➝ $16.004/28/2025INMDInModeNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/14/2025INMDInModeJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$16.00 ➝ $15.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMDInMode$394.82M2.43$1.82 per share8.31$10.12 per share1.50MDXGMiMedx Group$348.88M2.66$0.33 per share19.14$1.31 per share4.80NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72SIBNSiBone$167.18M4.71N/AN/A$3.98 per share4.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMDInMode$181.27M$2.336.508.33N/A44.79%17.17%15.20%7/30/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2723.2819.64N/A11.40%22.70%16.77%7/30/2025 (Estimated)NVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)SIBNSiBone-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)Latest NVRO, INMD, MDXG, and SIBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025MDXGMiMedx Group$0.06N/AN/AN/A$90.79 millionN/A5/5/2025Q1 2025SIBNSiBone-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million4/30/2025Q1 2025MDXGMiMedx Group$0.06$0.06N/A$0.05$86.32 million$88.21 million4/28/2025Q1 2025INMDInMode$0.45$0.31-$0.14$0.26$82.21 million$77.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMDInModeN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMDInModeN/A8.737.86MDXGMiMedx Group0.094.704.13NVRONevro0.675.023.76SIBNSiBone0.218.537.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMDInMode68.04%MDXGMiMedx Group79.15%NVRONevro95.52%SIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipINMDInMode6.92%MDXGMiMedx Group1.70%NVRONevro3.20%SIBNSiBone3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMDInMode48063.21 million58.84 millionOptionableMDXGMiMedx Group870147.70 million145.19 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableSIBNSiBone35042.62 million40.95 millionOptionableNVRO, INMD, MDXG, and SIBN HeadlinesRecent News About These CompaniesLisanti Capital Growth LLC Makes New Investment in SiBone (NASDAQ:SIBN)June 29, 2025 | marketbeat.comSI-BONE (NASDAQ:SIBN) Sees Unusually-High Trading Volume - Here's WhyJune 13, 2025 | marketbeat.comCantor Fitzgerald Weighs in on SI-BONE FY2026 EarningsJune 11, 2025 | marketbeat.comHarbor Capital Advisors Inc. Sells 308,333 Shares of SI-BONE, Inc. (NASDAQ:SIBN)June 10, 2025 | marketbeat.comCharter Oak Capital Management LLC Makes New $337,000 Investment in SI-BONE, Inc. (NASDAQ:SIBN)June 8, 2025 | marketbeat.comSI-BONE to Truist Securities MedTech Conference on June 17, 2025June 4, 2025 | globenewswire.comSI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025May 28, 2025 | globenewswire.comSI-BONE’s SWOT analysis: stock poised for growth amid market expansionMay 27, 2025 | investing.comWall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?May 26, 2025 | zacks.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 2,424 Shares of StockMay 21, 2025 | insidertrades.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 4,937 Shares of StockMay 16, 2025 | insidertrades.com4 Recent Earnings Winners Riding Fresh Momentum in May (SIBN)...May 14, 2025 | marketbeat.comWhat Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?May 13, 2025 | zacks.comEarnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsMay 9, 2025 | finance.yahoo.comWall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a BetMay 8, 2025 | zacks.comSI-BONE Inc. Q1 Loss Decreases, Beats EstimatesMay 7, 2025 | nasdaq.comSI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025May 6, 2025 | globenewswire.comSI-BONE, Inc. Reports Strong Q1 2025 GrowthMay 5, 2025 | tipranks.comSI-BONE, Inc. (SIBN) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comSi-Bone (SIBN) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2025 | zacks.comSI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 GuidanceMay 5, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVRO, INMD, MDXG, and SIBN Company DescriptionsInMode NASDAQ:INMD$15.16 -0.06 (-0.36%) Closing price 07/3/2025 03:31 PM EasternExtended Trading$15.16 +0.01 (+0.03%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.MiMedx Group NASDAQ:MDXG$6.28 +0.06 (+0.88%) Closing price 07/3/2025 03:00 PM EasternExtended Trading$6.16 -0.12 (-1.91%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.SiBone NASDAQ:SIBN$18.46 +0.03 (+0.16%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.